<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336582</url>
  </required_header>
  <id_info>
    <org_study_id>DOCXN101</org_study_id>
    <nct_id>NCT01336582</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of SYP-0704A and Taxotere to Treat Patient With Advanced Solid Cancer</brief_title>
  <official_title>Phase I Trial to Compare Pharmacokinetics and Safety of SYP-0704A With Taxotere in Subjects With Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samyang Biopharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samyang Biopharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective: Evaluation of the pharmacokinetic equivalence of two Docetaxel
      formulations in terms of AUC and Cmax.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison of pharmacokinetic parameters (T1/2β, CL, Vdss) Safety as measured by adverse
      events
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of SYP-0704A and Taxotere in terms of AUC</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the T1/2 of SYP-0704A and Taxotere</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the CL of SYP-0704A and Taxotere</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the Vdss of SYP-0704A and Taxotere</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of paticipants with Adverse Events</measure>
    <time_frame>3months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxotere</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Docetaxel-PM 75 mg/m2 (70 mg/m2 for age of ≥ 65) Taxotere 75mg/m2 (70 mg/m2 for age of ≥ 65)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>taxotere</intervention_name>
    <description>70 mg/m2 for age of ≥ 65</description>
    <arm_group_label>docetaxel</arm_group_label>
    <arm_group_label>Taxotere</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who aged 18 years or older.

          -  Subjects whose written informed consent was obtained complying with the local
             regulatory requirements prior to their participation in the trial.

          -  Subjects who have histologically or cytologically confirmed advanced solid tumor.

          -  Subjects who are a suitable candidate for single agent docetaxel therapy for their
             advanced solid tumors that have failed to standard therapy.

          -  Subjects who have fully recovered from reversible toxic effects of prior therapy. The
             prior chemotherapy, immunotherapy, hormone therapy, surgery, and/or radiotherapy
             should be completed at least 21 days before the first administration of
             investigational product.

        Exclusion Criteria:

          -  Subjects who have had a major surgery other than tumor ablation within 2 weeks prior
             to the screening/baseline visit.

          -  Subjects who have a history of metastasis or currently have a metastasis to the
             central nervous system (CNS).

          -  Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 2 based on NCI
             CTCAE V3.0.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin je gook, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje Pusan Paik university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inje Pusan paik University hospital</name>
      <address>
        <city>Pusan</city>
        <state>Jin-Gu</state>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>suitable candidate</keyword>
  <keyword>single agent docetaxel therapy</keyword>
  <keyword>Advanced Solid Tumor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

